Palo Alto Investors LP 13F holdings
Palo Alto Investors LP reported 52 positions with a total reported value of $1.4B as of 2026-06-30, in its 13F for Q2 2026, filed 2026-08-19. Top holdings by reported value: PTCT PTC THERAPEUTICS INC (10.7%), ACAD ACADIA PHARMACEUTICALS INC (10.3%), INSM INSMED INC (6.3%), ANAB ANAPTYSBIO INC (5.8%), BMRN BIOMARIN PHARMACEUTICAL INC (5.6%). Against 2026-03-31 it opened 3 new positions and exited 2. Next 13F due by 2026-11-14, the legal deadline 45 days after the quarter ending 2026-09-30.
Email me when Palo Alto Investors LP files its 13F
A free account follows up to 10 funds. New 13F filings arrive in your daily or weekly digest. No password and no card.
Top holdings
25 largest of 52 positions · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| PTCT PTC THERAPEUTICS INC | 1,837,692 | $149.9M | 10.7% |
| ACAD ACADIA PHARMACEUTICALS INC | 5,728,192 | $144.9M | 10.3% |
| INSM INSMED INC | 827,960 | $88.3M | 6.3% |
| ANAB ANAPTYSBIO INC | 1,206,978 | $81.5M | 5.8% |
| BMRN BIOMARIN PHARMACEUTICAL INC | 1,365,554 | $78.1M | 5.6% |
| DYN DYNE THERAPEUTICS INC | 3,295,042 | $73.2M | 5.2% |
| UTHR UNITED THERAPEUTICS CORP | 125,174 | $67.8M | 4.8% |
| IRON DISC MEDICINE INC | 833,292 | $60.9M | 4.3% |
| BIIB BIOGEN INC | 280,558 | $60.6M | 4.3% |
| IOVA IOVANCE BIOTHERAPEUTICS INC | 10,592,418 | $44.1M | 3.1% |
| MIRM MIRUM PHARMACEUTICALS INC | 348,808 | $40.8M | 2.9% |
| RARE ULTRAGENYX PHARMACEUTICAL IN | 1,192,990 | $39.8M | 2.8% |
| NVCR NOVOCURE LTD | 2,560,878 | $38.8M | 2.8% |
| SNDX SYNDAX PHARMACEUTICALS INC | 1,729,972 | $37.8M | 2.7% |
| ANNX ANNEXON INC | 5,896,180 | $33.7M | 2.4% |
| BCAX BICARA THERAPEUTICS INC | 1,100,816 | $32.7M | 2.3% |
| CDNA CAREDX INC | 1,063,740 | $30.3M | 2.2% |
| CLDX CELLDEX THERAPEUTICS INC | 799,712 | $29.8M | 2.1% |
| CMPX COMPASS THERAPEUTICS INC | 11,663,626 | $25.5M | 1.8% |
| ALKS ALKERMES PLC | 485,120 | $25.4M | 1.8% |
| TRAX FIRST TRACKS BIOTHERAPEUTICS | 1,206,978 | $24.3M | 1.7% |
| PROTHENA CORP PLC | 2,286,310 | $22.4M | 1.6% |
| TVTX TRAVERE THERAPEUTICS INC | 335,050 | $19.0M | 1.4% |
| TSHA TAYSHA GENE THERAPIES INC | 2,782,764 | $19.0M | 1.3% |
| ACRS ACLARIS THERAPEUTICS INC | 3,226,860 | $17.1M | 1.2% |
SEC FORM 13F · Q2 2026 · VALUES AS REPORTED, NOT PRICES
New positions this quarter
Held at 2026-06-30, not at 2026-03-31 · 3 in all · reported value as of 2026-06-30
Sold out
Held at 2026-03-31, gone by 2026-06-30 · 2 in all · reported value as of 2026-03-31
| Holding | Shares 2026-03-31 | Reported value | % of portfolio then |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 1,113,045 | $16.1M | 2.5% |
| DNLI DENALI THERAPEUTICS INC | 234,582 | $4.5M | 0.7% |
Biggest increases and decreases
Positions held at both quarter ends, by change in shares · reported value as of 2026-06-30
Increases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| PTCT PTC THERAPEUTICS INC | 921,607 | 1,837,692 | +99.4% | $149.9M |
| ACAD ACADIA PHARMACEUTICALS INC | 2,872,695 | 5,728,192 | +99.4% | $144.9M |
| INSM INSMED INC | 415,269 | 827,960 | +99.4% | $88.3M |
| BMRN BIOMARIN PHARMACEUTICAL INC | 685,182 | 1,365,554 | +99.3% | $78.1M |
| ANAB ANAPTYSBIO INC | 638,161 | 1,206,978 | +89.1% | $81.5M |
| DYN DYNE THERAPEUTICS INC | 1,652,972 | 3,295,042 | +99.3% | $73.2M |
| UTHR UNITED THERAPEUTICS CORP | 62,809 | 125,174 | +99.3% | $67.8M |
| IRON DISC MEDICINE INC | 401,719 | 833,292 | +107.4% | $60.9M |
| BIIB BIOGEN INC | 140,719 | 280,558 | +99.4% | $60.6M |
| CMPX COMPASS THERAPEUTICS INC | 1,514,504 | 11,663,626 | +670.1% | $25.5M |
| RARE ULTRAGENYX PHARMACEUTICAL IN | 596,495 | 1,192,990 | +100.0% | $39.8M |
| NVCR NOVOCURE LTD | 1,280,439 | 2,560,878 | +100.0% | $38.8M |
Decreases
No position was decreased.
CIK 1306923 · 13F FILINGS ON EDGAR · INFORMATIONAL ONLY
